AMG 386, an Angiogenesis Inhibitor, in the Treatment of Recurrent Ovarian, Peritoneal or Fallopian Tube CarcinomaAMG 386, an Angiogenesis Inhibitor, in the Treatment of Recurrent Ovarian, Peritoneal or Fallopian Tube Carcinoma
Slides from a presentation at ASCO 2010 and transcribed comments from a recent interview with Robert A Burger, MD (6/16/10)
Karlan BY et al. Randomized, double-blind, placebo-controlled, Phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. Proc ASCO 2010;Abstract 5000. |